The recent safety update to Rinvoq’s label is having the anticipated impact, AbbVie Inc.execs said during the firm’s fourth quarter and full year 2021 earnings call on 2 February, and the Janus kinase inhibitor is likely to return to growth in its lead indication of rheumatoid arthritis during the second quarter of 2022. Rinvoq, along with the IL-23 blocker Skyrizi, is a key cog in AbbVie’s strategy for enduring sales erosion of its top-seller Humira when US biosimilars of adalimumab begin entering the market in 2023.
AbbVie Says Rinvoq Holding Up, Humira Erosion Will Continue Into 2024
Physician response to FDA’s label change limiting Rinvoq to second-line-plus has been as expected, AbbVie said. Humira passed the $20bn sales threshold in 2021, but US biosimilar competition is one year away.
More from Earnings
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
More from Business
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.